|
SLC12A6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.09410036586155E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.74580041931461E-10 |
| Normal-vs-Stage2 |
8.43749999868137E-08 |
| Normal-vs-Stage3 |
2.542743793299E-12 |
| Normal-vs-Stage4 |
1.36500033498521E-10 |
| Stage1-vs-Stage2 |
6.555000E-01 |
| Stage1-vs-Stage3 |
3.926200E-01 |
| Stage1-vs-Stage4 |
1.136360E-01 |
| Stage2-vs-Stage3 |
8.824000E-01 |
| Stage2-vs-Stage4 |
4.361000E-01 |
| Stage3-vs-Stage4 |
4.125200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.66453525910038E-15 |
| Normal-vs-AfricanAmerican |
3.3621999995237E-07 |
| Normal-vs-Asian |
2.70790001533072E-09 |
| Caucasian-vs-AfricanAmerican |
9.351200E-01 |
| Caucasian-vs-Asian |
5.352800E-01 |
| AfricanAmerican-vs-Asian |
7.158800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.09069975273712E-10 |
| Normal-vs-Female |
1.79300019276241E-10 |
| Male-vs-Female |
5.927000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.65489999481849E-09 |
| Normal-vs-Age(41-60Yrs) |
1.04049990845567E-10 |
| Normal-vs-Age(61-80Yrs) |
6.17561557447743E-12 |
| Normal-vs-Age(81-100Yrs) |
9.838700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.956400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.156400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.701600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.130800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.107200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.216600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.345990E-01 |
| Classical-VS-Follicular |
5.257400E-01 |
| Classical-VS-Other |
9.008000E-01 |
| Classical-VS-Normal |
1.71400005299915E-09 |
| Tall-VS-Follicular |
4.661200E-01 |
| Tall-VS-Other |
4.089400E-01 |
| Tall-VS-Normal |
8.29940005608876E-10 |
| Follicular-VS-Other |
7.613400E-01 |
| Follicular-VS-Normal |
6.83940015733242E-10 |
| Other-VS-Normal |
1.284200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.94310148368982E-11 |
| Normal-vs-N1 |
2.67200039871796E-10 |
| N0-vs-N1 |
6.843200E-01 |
|
|
